Oncology Central

ESMO WCGI: Trifluridine and tipiracil show promise as metastatic gastric cancer treatment in Phase III trial

The Phase III clinical trial carried out by researchers at Taiho Oncology, Inc. (Tokyo, Japan) and Servier (Suresnes, France) evaluated trifluridine and tipiracil plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies.

Recently highlighted during the European Society for Medical Oncology 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) (20–23 June, Barcelona, Spain) the randomized double-blind trial met its primary endpoint of overall survival and secondary endpoint measures of progression-free survival (PFS), safety and tolerability, and quality of life.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.